Rubella and Pregnancy: Risks, Features, Diagnosis, and Management

Rubella, also known as German measles, is a viral infection caused by the togavirus. Thanks to the introduction of the MMR vaccine, it is now rare. However, if contracted during pregnancy, there is a risk of congenital rubella syndrome, which can cause serious harm to the fetus. It is important to note that the incubation period is 14-21 days, and individuals are infectious from 7 days before symptoms appear to 4 days after the onset of the rash.

The risk of damage to the fetus is highest in the first 8-10 weeks of pregnancy, with a risk as high as 90%. However, damage is rare after 16 weeks. Features of congenital rubella syndrome include sensorineural deafness, congenital cataracts, congenital heart disease (e.g. patent ductus arteriosus), growth retardation, hepatosplenomegaly, purpuric skin lesions, ‘salt and pepper’ chorioretinitis, microphthalmia, and cerebral palsy.

If a suspected case of rubella in pregnancy arises, it should be discussed immediately with the local Health Protection Unit (HPU) as type/timing of investigations may vary. IgM antibodies are raised in women recently exposed to the virus. It should be noted that it is very difficult to distinguish rubella from parvovirus B19 clinically. Therefore, it is important to also check parvovirus B19 serology as there is a 30% risk of transplacental infection, with a 5-10% risk of fetal loss.

If a woman is tested at any point and no immunity is demonstrated, they should be advised to keep away from people who might have rubella. Non-immune mothers should be offered the MMR vaccination in the post-natal period. However, MMR vaccines should not be administered to women known to be pregnant or attempting to become pregnant.

According to the guidelines of the Royal College, women who experience a fever of over 38 degrees Celsius during labor should be administered benzylpenicillin as a prophylactic measure against GBS.

Group B Streptococcus (GBS) is a common cause of severe infection in newborns. It is estimated that 20-40% of mothers carry GBS in their bowel flora, which can be passed on to their infants during labor and lead to serious infections. Prematurity, prolonged rupture of membranes, previous sibling GBS infection, and maternal pyrexia are all risk factors for GBS infection. The Royal College of Obstetricians and Gynaecologists (RCOG) has published guidelines on GBS management, which include not offering universal screening for GBS to all women and not offering screening based on maternal request. Women who have had GBS detected in a previous pregnancy should be offered intrapartum antibiotic prophylaxis (IAP) or testing in late pregnancy and antibiotics if still positive. IAP should also be offered to women with a previous baby with GBS disease, women in preterm labor, and women with a fever during labor. Benzylpenicillin is the preferred antibiotic for GBS prophylaxis.

When managing shoulder dystocia, it is important to call for extra assistance immediately. Avoid using fundal pressure and note that an episiotomy may not always be required. Inducing labor at term can lower the occurrence of shoulder dystocia in women with gestational diabetes. The McRoberts manoeuvre is the preferred initial intervention due to its simplicity, speed, and effectiveness in most cases. These guidelines are based on the RCOG Green-top guideline no. 42 from March 2012 on Shoulder Dystocia.

Shoulder dystocia is a complication that can occur during vaginal delivery when the body of the fetus cannot be delivered after the head has already been delivered. This is usually due to the anterior shoulder of the fetus becoming stuck on the mother’s pubic bone. Shoulder dystocia can cause harm to both the mother and the fetus. Risk factors for shoulder dystocia include fetal macrosomia, high maternal body mass index, diabetes mellitus, and prolonged labor.

If shoulder dystocia is identified, it is important to call for senior help immediately. The McRoberts’ maneuver is often performed, which involves flexing and abducting the mother’s hips to increase the angle of the pelvis and facilitate delivery. An episiotomy may be performed to provide better access for internal maneuvers, but it will not relieve the bony obstruction. Symphysiotomy and the Zavanelli maneuver are not recommended as they can cause significant maternal morbidity. Oxytocin administration is not indicated for shoulder dystocia.

Complications of shoulder dystocia can include postpartum hemorrhage and perineal tears for the mother, and brachial plexus injury and neonatal death for the fetus. It is important to manage shoulder dystocia promptly and appropriately to minimize the risk of these complications.

Continuous CTG monitoring is recommended during labour if any of the following conditions are present or develop: suspected chorioamnionitis or sepsis, a temperature of 38°C or higher, severe hypertension with a reading of 160/110 mmHg or above, use of oxytocin, or significant meconium. In addition, the 2014 update to the guidelines added fresh vaginal bleeding as a new point of concern, as it may indicate placental rupture or placenta previa, both of which require monitoring of the baby.

Cardiotocography (CTG) is a medical procedure that measures pressure changes in the uterus using either internal or external pressure transducers. It is used to monitor the fetal heart rate, which normally ranges between 100-160 beats per minute. There are several features that can be observed during a CTG, including baseline bradycardia (heart rate below 100 beats per minute), which can be caused by increased fetal vagal tone or maternal beta-blocker use. Baseline tachycardia (heart rate above 160 beats per minute) can be caused by maternal pyrexia, chorioamnionitis, hypoxia, or prematurity. Loss of baseline variability (less than 5 beats per minute) can be caused by prematurity or hypoxia. Early deceleration, which is a decrease in heart rate that starts with the onset of a contraction and returns to normal after the contraction, is usually harmless and indicates head compression. Late deceleration, on the other hand, is a decrease in heart rate that lags behind the onset of a contraction and does not return to normal until after 30 seconds following the end of the contraction. This can indicate fetal distress, such as asphyxia or placental insufficiency. Variable decelerations, which are independent of contractions, may indicate cord compression.

Understanding Risk Factors for Intrauterine Growth Restriction (IUGR)

Intrauterine growth restriction (IUGR) is a condition where a baby does not grow properly in the womb. There are various risk factors associated with IUGR, including smoking during pregnancy, which can increase the likelihood of developing the condition.

There are two types of IUGR: symmetrical and asymmetrical. Symmetrical growth retardation occurs at the start or during early pregnancy and is characterized by a small head and short length. Asymmetrical growth retardation occurs in advanced pregnancy and is characterized by reduced abdominal growth compared to head circumference, due to selective shunting of blood to the brain.

It’s important to note that a baby with a birthweight below the tenth centile is considered small for gestational age (SGA), which may be normal or due to IUGR.

Contrary to popular belief, hypotension (low blood pressure), obesity, and stress are not recognized risk factors for IUGR. However, poorly controlled diabetes is a risk factor for IUGR, while well-controlled diabetes is not.

Understanding these risk factors can help healthcare providers identify and manage IUGR early on, leading to better outcomes for both mother and baby.

The first stage of labour begins with the onset of true labour and ends when the cervix is fully dilated at 10cm. During this stage, regular contractions occur and the cervix gradually dilates. It is important to note that although 4 cm and 6cm cervical dilation occur during this stage, it does not end until the cervix is fully effaced at 10cm. The second stage of labour ends with the birth of the foetus, not the first.

Labour is divided into three stages, with the first stage beginning from the onset of true labour until the cervix is fully dilated. This stage is further divided into two phases: the latent phase and the active phase. The latent phase involves dilation of the cervix from 0-3 cm and typically lasts around 6 hours. The active phase involves dilation from 3-10 cm and progresses at a rate of approximately 1 cm per hour. In primigravidas, this stage can last between 10-16 hours.

During this stage, the baby’s presentation is important to note. Approximately 90% of babies present in the vertex position, with the head entering the pelvis in an occipito-lateral position. The head typically delivers in an occipito-anterior position.

The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after a minimum of 4 weeks. However, it is important to note that insertion between 48 hours and 4 weeks after delivery should be avoided due to the increased risk of expulsion and lack of data on uterine perforation with newer models. In addition to general contraindications, contraindications to postpartum insertion within 48 hours include peripartum chorioamnionitis, endometritis, puerperal sepsis, or post-partum haemorrhage. Waiting a minimum of 6 weeks or 2 months after delivery is not necessary. If waiting the recommended minimum of 4 weeks, the progesterone-only pill may be used as an interim measure to reduce the risk of pregnancy.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Safe Pain Management Options for Breastfeeding Mothers

Breastfeeding mothers who experience pain may require medication to manage their symptoms. However, certain drugs can be harmful to both the mother and the baby. Here are some safe pain management options for breastfeeding mothers:

Ibuprofen: This is the drug of choice for managing pain in breastfeeding mothers. Although it is contraindicated in pregnancy, its transfer into breast milk is very low.

Codeine: This opioid analgesic can be used during pregnancy, but it should be avoided as the mother approaches delivery due to the risk of respiratory depression in the infant. It should also be avoided when breastfeeding, as it can cause symptoms of overdose in the baby.

Aspirin: While aspirin is used during pregnancy for prophylaxis, its use as an analgesic should be avoided during breastfeeding as it can cause Reye’s syndrome or impair neonatal platelet function.

Indometacin: This NSAID can be used for analgesia in breastfeeding, as the concentration that transfers into breast milk is relatively low.

Tramadol: Although only small amounts of this opioid analgesic are present in breast milk, the manufacturers advise avoidance due to the risk of respiratory depression in the baby.

It is important to consult with a healthcare provider before taking any medication while breastfeeding. Additionally, mothers should be aware of any contraindications and potential side effects of the medication they are taking.

Puerperal psychosis is a condition that manifests as a sudden onset of manic or psychotic symptoms shortly after giving birth. Any sudden change in mental state should be considered a warning sign for puerperal psychosis. On the other hand, the baby blues is a milder form of depression that typically lasts only a few days after childbirth. While postpartum depression can also involve psychosis, it usually appears within the first month after delivery. Furthermore, manic symptoms such as restlessness, racing thoughts, and pressured speech are unlikely to occur in a depressive episode.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

Recommendations for Feeding Low-Birthweight Infants

Low-birthweight infants, those with a birthweight of less than 2,500 g, should be exclusively breastfed for the first six months of life, according to WHO recommendations. If the mother’s milk is not available, donor human milk should be sought. If that is not possible, standard formula milk can be used. There is no difference in the duration of exclusive breastfeeding between low-birthweight and normal-weight infants. Daily vitamin A supplementation is not currently recommended for low-birthweight infants, but very low-birthweight infants should receive daily supplementation of vitamin D, calcium, and phosphorus. Low-birthweight infants who are able to breastfeed should start as soon as possible after birth, once they are clinically stable.

The correct answer is that magnesium sulphate treatment should continue for 24 hours after delivery or the last seizure. This treatment is used to prevent and treat seizures in mothers with eclampsia. In this case, the patient is showing signs of eclampsia due to high protein levels in her urine, pregnancy-induced hypertension, and seizures. Therefore, she needs to be admitted and continue magnesium treatment for 24 hours after delivery or the last seizure. Magnesium helps prevent seizures by relaxing smooth muscle tissues and slowing uterine contractions. Labetalol is not the correct answer as it is used for long-term treatment of hypertension, which may not be necessary for this patient after delivery. Nifedipine with hydralazine may be more suitable for her hypertension as she is asthmatic. Magnesium sulphate treatment for 12 or 48 hours after delivery or the last seizure is not recommended according to guidelines, which suggest 24 hours is the appropriate duration.

Understanding Eclampsia and its Treatment

Eclampsia is a condition that occurs when seizures develop in association with pre-eclampsia, a pregnancy-induced hypertension that is characterized by proteinuria and occurs after 20 weeks of gestation. To prevent seizures in patients with severe pre-eclampsia and treat seizures once they develop, magnesium sulphate is commonly used. However, it is important to note that this medication should only be given once a decision to deliver has been made. In cases of eclampsia, an IV bolus of 4g over 5-10 minutes should be given, followed by an infusion of 1g/hour. During treatment, it is crucial to monitor urine output, reflexes, respiratory rate, and oxygen saturations. Respiratory depression can occur, and calcium gluconate is the first-line treatment for magnesium sulphate-induced respiratory depression. Treatment should continue for 24 hours after the last seizure or delivery, as around 40% of seizures occur post-partum. Additionally, fluid restriction is necessary to avoid the potentially serious consequences of fluid overload.

In summary, understanding the development of eclampsia and its treatment is crucial in managing this potentially life-threatening condition. Magnesium sulphate is the primary medication used to prevent and treat seizures, but it should only be given once a decision to deliver has been made. Monitoring vital signs and urine output is essential during treatment, and calcium gluconate should be readily available in case of respiratory depression. Finally, fluid restriction is necessary to avoid complications associated with fluid overload.

Cardiotocography (CTG) is a medical procedure that measures pressure changes in the uterus using either internal or external pressure transducers. It is used to monitor the fetal heart rate, which normally ranges between 100-160 beats per minute. There are several features that can be observed during a CTG, including baseline bradycardia (heart rate below 100 beats per minute), which can be caused by increased fetal vagal tone or maternal beta-blocker use. Baseline tachycardia (heart rate above 160 beats per minute) can be caused by maternal pyrexia, chorioamnionitis, hypoxia, or prematurity. Loss of baseline variability (less than 5 beats per minute) can be caused by prematurity or hypoxia. Early deceleration, which is a decrease in heart rate that starts with the onset of a contraction and returns to normal after the contraction, is usually harmless and indicates head compression. Late deceleration, on the other hand, is a decrease in heart rate that lags behind the onset of a contraction and does not return to normal until after 30 seconds following the end of the contraction. This can indicate fetal distress, such as asphyxia or placental insufficiency. Variable decelerations, which are independent of contractions, may indicate cord compression.

Women with postpartum psychosis require hospitalisation, ideally in a Mother & Baby Unit, for close monitoring. This is a serious mental illness that should be treated as a medical emergency, and electroconvulsive therapy is not the next step in management.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

Physiological Changes in Pregnancy

Pregnancy is a time of significant physiological changes in a woman’s body. These changes are mainly driven by progesterone rather than oestrogen. One of the changes is vasodilation, which leads to a drop in blood pressure initially, but it normalizes by term. However, an increase in heart rate and stroke volume leads to an increase in cardiac output.

Another change is a decrease in lower oesophageal sphincter tone and vascular resistance, which causes a drop in blood pressure. This decrease occurs over the first trimester but starts to increase to normal by term. Oestrogen is responsible for this change, and it also causes symptoms of reflux.

Pregnancy also causes a mild anaemia due to a drop in red cell volume. However, this is a dilutional anaemia caused by an increase in plasma volume. Additionally, there is an increase in clotting factors II, VII, IX, and X, which makes pregnancy a hypercoagulable state.

The functional residual capacity (FRC) increases in pregnancy, leading to more rapid breathing and smaller tidal volumes. This decrease in FRC means that oxygen reserve is less in pregnant women. Minute ventilation increases due to increased oxygen consumption and increased CO2 production. This is by increased tidal volume rather than respiratory rate.

Finally, the glomerular filtration rate (GFR) decreases secondary to progesterone, facilitating an increase in fluid retention and an increase in plasma volume. However, there is also an increase in aldosterone, which acts on the kidneys producing water and sodium retention, therefore causing an increase in plasma volume.

In conclusion, pregnancy causes significant physiological changes in a woman’s body, which are mainly driven by progesterone. These changes affect various systems, including the cardiovascular, respiratory, and renal systems.

This patient is suffering from severe pre-eclampsia, evidenced by moderate hypertension and symptoms of headache and vomiting. According to NICE guidelines, delivery should be carried out within 24-48 hours for women with pre-eclampsia and mild to moderate hypertension after 37 weeks. Magnesium sulphate is recommended for the treatment of severe hypertension or pre-eclampsia in women who have already experienced seizures. IV magnesium sulphate should also be considered if delivery is planned within 24 hours or if there is a risk of eclampsia. Although IV hydralazine may lower blood pressure, immediate delivery and protection against eclampsia are required due to the patient’s presenting symptoms. IM beclomethasone is unnecessary as the patient is past 36 weeks. IV calcium gluconate is used to treat magnesium toxicity and is not indicated in this case. While delivery should be planned, the patient also requires protection against the development of eclampsia and seizures.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

If a woman with stage IA cervical cancer wants to maintain her fertility, a cone biopsy with negative margins and close follow-up may be considered as the best option. Hysterectomy with or without lymph node clearance would not preserve fertility. Radical trachelectomy, which involves removing the cervix, upper part of the vagina, and surrounding tissues, and checking for cancer spread in the pelvis, is an option for IA2 tumors that also preserves fertility.

Management of Cervical Cancer Based on FIGO Staging

Cervical cancer management is determined by the FIGO staging and the patient’s desire to maintain fertility. The FIGO staging system categorizes cervical cancer into four stages based on the extent of the tumor’s spread. Stage IA and IB tumors are confined to the cervix, with IA tumors only visible under a microscope and less than 7 mm wide. Stage II tumors have spread beyond the cervix but not to the pelvic wall, while stage III tumors have spread to the pelvic wall. Stage IV tumors have spread beyond the pelvis or involve the bladder or rectum.

The management of stage IA tumors involves a hysterectomy with or without lymph node clearance. For patients who want to maintain fertility, a cone biopsy with negative margins can be performed, but close follow-up is necessary. Stage IB tumors are managed with radiotherapy and concurrent chemotherapy for B1 tumors and radical hysterectomy with pelvic lymph node dissection for B2 tumors.

Stage II and III tumors are managed with radiation and concurrent chemotherapy, with consideration for nephrostomy if hydronephrosis is present. Stage IV tumors are treated with radiation and/or chemotherapy, with palliative chemotherapy being the best option for stage IVB. Recurrent disease is managed with either surgical treatment followed by chemoradiation or radiotherapy followed by surgical therapy.

The prognosis of cervical cancer depends on the FIGO staging, with higher survival rates for earlier stages. Complications of treatments include standard surgical risks, increased risk of preterm birth with cone biopsies and radical trachelectomy, and ureteral fistula with radical hysterectomy. Complications of radiotherapy include short-term symptoms such as diarrhea and vaginal bleeding and long-term effects such as ovarian failure and fibrosis of various organs.

If blood glucose targets are not achieved through diet and metformin in gestational diabetes, insulin should be introduced as the next step. This is in accordance with current NICE guidelines, which recommend that pregnant women with any form of diabetes aim for plasma glucose levels below specific target values. Commencing anti-emetic medications or metformin would not be the most appropriate options in this scenario, as the former would not address the underlying issue of gestational diabetes and the latter is not acceptable to the patient. Additionally, offering a 2 week trial of diet and exercise changes would not be appropriate at this stage, as medication is now required. However, this may be an option for patients with a fasting plasma glucose of between 6.0 and 6.9 mmol/L without complications, who can be offered a trial of diet and exercise for 2 weeks before medication is considered if blood glucose targets are not met.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

When a woman has gestational diabetes, it is important to control her blood glucose levels to prevent complications such as premature birth, stillbirth, and macrosomia. If diet and exercise changes along with metformin do not meet blood glucose targets, insulin therapy should be added, according to NICE guidelines. Sulfonylureas are not recommended for gestational diabetes as they are less effective than the metformin and insulin combination and have been shown to be teratogenic in animals. Metformin should not be stopped as it increases insulin sensitivity, which is lacking during pregnancy. SGLT-2 antagonists are also not recommended due to their teratogenic effects in animals. Continuing metformin alone for two weeks despite high blood glucose levels increases the risk of complications, so insulin therapy should be added at this stage.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

When managing mastitis in breastfeeding women, it is recommended to continue breastfeeding while using simple analgesia and warm compresses. If breastfeeding is too painful, expressing milk by hand or using a pump is advised to prevent milk stasis, which is often the cause of lactational mastitis. According to NICE clinical knowledge summaries (CKS), oral antibiotics are only necessary if there is an infected nipple fissure, symptoms do not improve after 12-24 hours despite effective milk removal, or breast milk culture is positive. Flucloxacillin is the first-line antibiotic for 10-14 days, while erythromycin or clarithromycin can be used for penicillin-allergic patients. Referral to a surgical team in the hospital is only necessary if a breast abscess is suspected, which is unlikely if there is no palpable lump in the breast.

Breastfeeding Problems and Their Management

Breastfeeding is a natural process, but it can come with its own set of challenges. Some of the minor problems that breastfeeding mothers may encounter include frequent feeding, nipple pain, blocked ducts, and nipple candidiasis. These issues can be managed by seeking advice on proper positioning, trying breast massage, and using appropriate medication.

Mastitis is a more serious problem that affects around 1 in 10 breastfeeding women. It is characterized by symptoms such as fever, nipple fissure, and persistent pain. Treatment involves the use of antibiotics, such as flucloxacillin, for 10-14 days. Breastfeeding or expressing milk should continue during treatment to prevent complications such as breast abscess.

Breast engorgement is another common problem that causes breast pain in breastfeeding women. It occurs in the first few days after birth and affects both breasts. Hand expression of milk can help relieve the discomfort of engorgement. Raynaud’s disease of the nipple is a less common problem that causes nipple pain and blanching. Treatment involves minimizing exposure to cold, using heat packs, and avoiding caffeine and smoking.

If a breastfed baby loses more than 10% of their birth weight in the first week of life, it may be a sign of poor weight gain. This should prompt consideration of the above breastfeeding problems and an expert review of feeding. Monitoring of weight should continue until weight gain is satisfactory.

Understanding Miscarriage: Types and Recurrence Rates

Miscarriage is a common experience for many women, but it can still be a difficult and emotional event. It is defined as any pregnancy loss that occurs before 24 weeks of gestation. There are several types of miscarriage, including threatened, inevitable, incomplete, complete, missed, anembryonic, septic, and recurrent. Recurrent miscarriage, which is defined as three or more consecutive losses, is a particular concern for many women. The risk of recurrence is important to consider when offering parental counseling, as it can impact the chances of a successful pregnancy. For women without specific cause for recurrence, the percentage chance of a live birth in a subsequent pregnancy decreases with each miscarriage: 85% after one, 75% after two, and 60% after three. It’s important to remember that while miscarriage can be distressing, the chances of a successful pregnancy increase with each attempt.

Antepartum Haemorrhage: Causes and Symptoms

Antepartum haemorrhage is a condition where a pregnant woman experiences vaginal bleeding during the second half of pregnancy. There are several causes of antepartum haemorrhage, including placental abruption, concealed placental abruption, placenta accreta, placenta praevia, and premature labour.

Placental abruption is a condition where the placenta separates from the uterine lining, leading to bleeding. It can be revealed, with vaginal bleeding, or concealed, without vaginal bleeding. Risk factors for placental abruption include maternal hypertension, smoking, cocaine use, trauma, and bleeding post-procedures.

Concealed placental abruption is usually an incidental finding, with the mother recalling an episode of pain without vaginal bleeding. Placenta accreta occurs when part of the placenta grows into the myometrium, causing severe intrapartum and postpartum haemorrhage. Placenta praevia is a low-lying placenta that can cause painless vaginal bleeding and requires an elective Caesarean section. Premature labour is another common cause of antepartum bleeding associated with abdominal pain, with cyclical pain and variable vaginal bleeding.

It is important to seek medical attention if experiencing antepartum haemorrhage, as it can lead to significant maternal and fetal morbidity and mortality. Women with placenta praevia are advised to attend the Antenatal Unit for assessment and monitoring every time they have bleeding.

The symptoms and time frame mentioned in the question strongly suggest an amniotic fluid embolism, which typically occurs during or within 30 minutes of labor and is characterized by respiratory distress, hypoxia, and hypotension. On the other hand, intracranial hemorrhage is usually preceded by a severe headache, while convulsions are indicative of eclampsia and drug toxicity. The symptoms experienced by the patient during normal labor would not be expected in cases of drug toxicity. Additionally, hypoxia is not a typical symptom of drug toxicity.

Amniotic fluid embolism is a rare but serious complication of pregnancy that can result in a high mortality rate. It occurs when fetal cells or amniotic fluid enter the mother’s bloodstream, triggering a reaction that leads to various signs and symptoms. While several risk factors have been associated with this condition, such as maternal age and induction of labor, the exact cause remains unclear. It is believed that exposure of maternal circulation to fetal cells or amniotic fluid is necessary for the development of an amniotic fluid embolism, but the underlying pathology is not well understood.

The majority of cases of amniotic fluid embolism occur during labor, but they can also occur during a cesarean section or in the immediate postpartum period. Symptoms of this condition include chills, shivering, sweating, anxiety, and coughing, while signs may include cyanosis, hypotension, bronchospasms, tachycardia, arrhythmia, and myocardial infarction. Diagnosis is primarily clinical and based on exclusion, as there are no definitive diagnostic tests available.

Management of amniotic fluid embolism requires a multidisciplinary team and critical care unit. Treatment is mainly supportive, focusing on addressing the patient’s symptoms and stabilizing their condition. Given the high mortality rate associated with this condition, prompt recognition and management are crucial for improving outcomes.

During the term of pregnancy, there is ample space for the fetus to reposition itself and move towards the head-down position. However, in cases of occipitoposterior presentation, the posterior fontanelle is located in the back quadrant of the pelvis, which requires more rotation and often results in a longer labor. Additionally, there is a higher likelihood of medical intervention, with a rate of 22.

Breech presentation occurs when the caudal end of the fetus is in the lower segment, and it is more common at 28 weeks than near term. Risk factors include uterine malformations, placenta praevia, and fetal abnormalities. Management options include spontaneous turning, external cephalic version (ECV), planned caesarean section, or vaginal delivery. The RCOG recommends informing women that planned caesarean section reduces perinatal mortality and early neonatal morbidity, but there is no evidence that the long-term health of babies is influenced by how they are born. ECV is contraindicated in certain cases, such as where caesarean delivery is required or there is an abnormal cardiotocography.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Placental abruption is a critical obstetric emergency that requires immediate attention to prevent severe blood loss and potential harm to both the mother and baby. While patients have the right to choose their doctor, this right does not apply in emergency situations where prompt treatment is necessary to save the patient’s life. Therefore, suggesting that the patient wait for a female doctor or return in an hour is inappropriate and could result in a dangerous delay in medical care. It is also unnecessary to label the comment as sexist and document it in the patient’s notes. While it is important to respect the patient’s preferences, the priority in this situation is to provide urgent medical attention. Similarly, asking a midwife to take on the role of a doctor is not a safe or appropriate solution, as their training and responsibilities differ. Ultimately, if a female doctor is not available, the patient must be treated by a male doctor to address the emergency as quickly and effectively as possible.

Placental Abruption: Causes, Symptoms, and Risk Factors

Placental abruption is a condition that occurs when the placenta separates from the uterine wall, leading to maternal bleeding into the space between them. Although the exact cause of this condition is unknown, certain factors have been associated with it, including proteinuric hypertension, cocaine use, multiparity, maternal trauma, and increasing maternal age. Placental abruption is not a common occurrence, affecting approximately 1 in 200 pregnancies.

The clinical features of placental abruption include shock that is disproportionate to the visible blood loss, constant pain, a tender and tense uterus, and a normal lie and presentation of the fetus. The fetal heart may be absent or distressed, and there may be coagulation problems. It is important to be aware of other conditions that may present with similar symptoms, such as pre-eclampsia, disseminated intravascular coagulation (DIC), and anuria.

In summary, placental abruption is a serious condition that can have significant consequences for both the mother and the fetus. Understanding the risk factors and symptoms of this condition is important for early detection and appropriate management.

A study conducted in Norway in 2006 revealed that singleton pregnancies conceived through assisted fertilization had a six-fold higher risk of placenta praevia compared to naturally conceived pregnancies. The risk of placenta previa was also nearly three-fold higher in pregnancies following assisted fertilization for mothers who had conceived both naturally and through assisted fertilization. This abnormal placental placement is believed to be linked to the abnormal ovarian stimulation hormones that occur during IVF. Additionally, the incidence of placenta praevia is associated with previous caesarean sections, multiparity, and previous gynaecological surgeries, while the incidence of other options given increases with the number of previous caesarean sections.

Understanding Placenta Praevia

Placenta praevia is a condition where the placenta is located wholly or partially in the lower uterine segment. It is a relatively rare condition, with only 5% of women having a low-lying placenta when scanned at 16-20 weeks gestation. However, the incidence at delivery is only 0.5%, as most placentas tend to rise away from the cervix.

There are several factors associated with placenta praevia, including multiparity, multiple pregnancy, and embryos implanting on a lower segment scar from a previous caesarean section. Clinical features of placenta praevia include shock in proportion to visible loss, no pain, a non-tender uterus, abnormal lie and presentation, and a usually normal fetal heart. Coagulation problems are rare, and small bleeds may occur before larger ones.

Diagnosis of placenta praevia should not involve digital vaginal examination before an ultrasound, as this may provoke severe haemorrhage. The condition is often picked up on routine 20-week abdominal ultrasounds, but the Royal College of Obstetricians and Gynaecologists recommends the use of transvaginal ultrasound for improved accuracy and safety. Placenta praevia is classified into four grades, with grade IV being the most severe, where the placenta completely covers the internal os.

In summary, placenta praevia is a rare condition that can have serious consequences if not diagnosed and managed appropriately. It is important for healthcare professionals to be aware of the associated factors and clinical features, and to use appropriate diagnostic methods for accurate grading and management.

According to the National Institute for Health and Care Excellence (NICE), if a woman has an unruptured ectopic pregnancy measuring less than 35mm without visible heartbeat, a serum B-hCG level of less than 1500 IU/L, no intrauterine pregnancy, and no pain, the recommended first-line treatment is methotrexate, provided the patient is willing to attend follow-up appointments. However, if the woman declines expectant management, which is an option for a small number of women with low B-hCG, no symptoms, and a tubal ectopic pregnancy measuring less than 35mm without heartbeat, methotrexate is the preferred treatment option. Methotrexate is a chemotherapeutic drug that interferes with DNA synthesis and disrupts cell multiplication, preventing the pregnancy from developing. Laparoscopic salpingectomy (or salpingostomy if there is a risk of infertility) is the other treatment option, which should be offered if the ectopic pregnancy is larger than 35mm, causing severe pain, or if the B-hCG level is greater than 1500. However, there is a risk of infertility if a problem arises with the remaining Fallopian tube in the future. Misoprostol and mifepristone are not recommended for the management of ectopic pregnancy.

Understanding Ectopic Pregnancy

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus. This condition is characterized by lower abdominal pain and vaginal bleeding, typically occurring 6-8 weeks after the start of the last period. The pain is usually constant and may be felt on one side of the abdomen due to tubal spasm. Vaginal bleeding is usually less than a normal period and may be dark brown in color. Other symptoms may include shoulder tip pain, pain on defecation/urination, dizziness, fainting, or syncope. Breast tenderness may also be reported.

During examination, abdominal tenderness and cervical excitation may be observed. However, it is not recommended to examine for an adnexal mass due to the risk of rupturing the pregnancy. Instead, a pelvic examination to check for cervical excitation is recommended. In cases of pregnancy of unknown location, serum bHCG levels >1,500 may indicate an ectopic pregnancy. It is important to seek medical attention immediately if ectopic pregnancy is suspected as it can be life-threatening.

The presence of Down’s syndrome can be indicated by an increase in beta-HCG, a decrease in PAPP-A, and the observation of a thickened nuchal translucency during ultrasound. The other options involving beta-HCG and PAPP-A are incorrect. The combined screening test is usually conducted between the 10th and 14th week of pregnancy and involves an ultrasound to measure nuchal thickness, as well as blood tests to assess beta-HCG and PAPP-A levels. A positive result suggests a higher risk of Down’s syndrome, Patau’s syndrome, and Edward’s syndrome. In such cases, amniocentesis, chorionic villus sampling, or non-invasive prenatal testing may be offered to confirm the diagnosis. The options involving inhibin A are not part of the combined screening test. If a woman presents later in pregnancy, the quadruple test may be used instead, which involves four blood markers to determine the risk of Down’s syndrome. These markers include inhibin A, alpha-fetoprotein, unconjugated oestriol, and beta-HCG. A positive result for Down’s syndrome would typically show raised beta-HCG and inhibin A, and low unconjugated oestriol and alpha-fetoprotein.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

A transvaginal ultrasound is the preferred method of investigation for ectopic pregnancy.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Women who have recently given birth, whether they are breastfeeding or not, can begin taking the progesterone-only pill at any time. However, for this patient who is only 2 days postpartum, it is recommended to prescribe the progesterone-only pill as it does not contain estrogen and is less likely to affect milk production. Additionally, it does not increase the risk of venous thromboembolism, which is a concern for postpartum women until 21-28 days after giving birth. The combined oral contraceptive pill should be avoided until 21 days postpartum due to the risk of thrombosis and reduced breast milk production. The patient cannot resume her previous contraceptives at this time. While an intrauterine device can be inserted during a caesarean section, it is advisable to wait 4-6 weeks postpartum before having it inserted vaginally. It is incorrect to tell the patient that she cannot use any contraception if she wishes to breastfeed, as the progesterone-only pill has been shown to have minimal effect on milk production in breastfeeding women.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.